PRimage.jpg
INVESTOR ALERT: Kaplan Fox Investigates Mersana Therapeutics, Inc. (Nasdaq: MRSN)
19 juin 2023 18h54 HE | Kaplan Fox & Kilsheimer LLP
NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Mersana Therapeutics, Inc....
mersana_logo.png
Mersana Therapeutics Announces Appointment of Brian C. DeSchuytner as Senior Vice President of Finance and Product Strategy
12 juin 2019 08h00 HE | Mersana Therapeutics, Inc.
            Brings Significant Strategic and Operational Experience from Leading Oncology Companies Company Announces Chief Financial Officer Transition CAMBRIDGE, Mass., June 12, 2019 (GLOBE...
mersana_logo.png
Mersana Therapeutics Appoints Dirk Huebner, M.D., as Chief Medical Officer
27 nov. 2018 08h00 HE | Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
mersana_logo.png
Mersana Therapeutics Announces Third Quarter 2018 Financial Results and Provides Business Updates
13 nov. 2018 07h00 HE | Mersana Therapeutics, Inc.
XMT-1536 Phase 1 Dose Escalation Ongoing with Data Expected in the First Half of 2019 XMT-1522 Phase 1 Dose Escalation Enrollment Resumed Mersana to Present New Data on Dolasynthen and...
mersana_logo.png
Mersana Therapeutics Presents Pre-clinical Data at AACR-NCI-EORTC on Two Additional, Proprietary Antibody Drug Conjugate Platforms and a Pre-clinical Update for XMT-1522 in Non-small Cell Lung Cancer
12 nov. 2018 09h00 HE | Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
mersana_logo.png
Mersana Scientists Present Updates on XMT-1522, XMT-1536 and the Dolaflexin Platform at World ADC 2018
12 nov. 2018 07h00 HE | Mersana Therapeutics, Inc.
Mersana Chief Scientific Officer, Timothy B. Lowinger, Ph.D. to chair 2018 Conference CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage...
mersana_logo.png
Mersana Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference
08 nov. 2018 17h00 HE | Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
mersana_logo.png
Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2018 Financial Results and Business Updates
06 nov. 2018 17h00 HE | Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
mersana_logo.png
Mersana Therapeutics to Present at Upcoming Investor Conferences
26 sept. 2018 16h03 HE | Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
mersana_logo.png
Mersana Therapeutics Presents New Preclinical Data on XMT-1536 at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer
25 sept. 2018 08h00 HE | Mersana Therapeutics, Inc.
Novel Immunohistochemistry Assay Distinguishes Non-Small Cell Lung Cancer (NSCLC) Subtypes XMT-1536 Phase 1 Dose Escalation Ongoing With Data Reporting in the First Half of 2019 CAMBRIDGE, Mass.,...